<DOC>
	<DOCNO>NCT00914355</DOCNO>
	<brief_summary>This study design see whether stereotactic body radiation therapy ( SBRT ) reduce tumour size , slow progression disease , prolong life improve quality life patient hepatocellular carcinoma , cancer liver , remove surgically ( unresectable ) treat ablative therapy ( e.g . radio-frequency ablation ) trans-arterial chemo-embolization ( TACE ) therapy ( delivery chemotherapy artery feed liver ) . SBRT concentrate focused radiation therapy deliver precisely liver tumour . It hop knowledge obtain study improve ability treat patient liver tumour treat surgery method , SBRT may prove treatment lead long-term permanent control liver tumours patient .</brief_summary>
	<brief_title>Stereotactic Body Radiation Therapy ( SBRT ) Hepatocellular Carcinoma ( COLD 2 )</brief_title>
	<detailed_description>From July 2003 May 2007 , 40 patient hepatocellular carcinoma participate two study Princess Margaret Hospital ( PMH ) design determine safety treat hepatocellular carcinoma SBRT . These study show SBRT deliver safely majority patient hepatocellular carcinoma . The treated tumour control ( shrank remain size ) 78 % patient one year follow treatment.The median survival patient 11 month ( i.e . half patient survive longer half short 11 month ) . This survival rate well expect patient treat supportive care ( treatment care make feel good ) . Supportive care patient median survival rate 3-9 month . We expect benefit SBRT study similar observe initial study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Confirmed pathologically , 2 ) diagnose show vascular enhancement lesion least two image technique , 3 ) diagnose show vascular enhancement single technique AFP great 200 , set cirrhosis chronic hepatitis B without cirrhosis ( EASL consensus conference guideline ) . Either 1 ) tumour must unresectable , base opinion experience surgeon specialize hepatic resection , 2 ) patient Phase II SBRT HCC 13 must medically inoperable , 3 ) extrahepatic metastasis must present ( make hepatic surgery inappropriate treatment option ) . Karnofsky performance status ( KPS ) &gt; 60 ( Appendix II ) Age : 18 year old . Both male &amp; female patient race include study . Female patient within reproductive year may , become , pregnant participation study Patients must recover effect previous therapy . Maximal tumor size 15 cm . Adequate organ function assess follow : Hemoglobin &gt; 90 g/L Absolute neutrophil count &gt; 1.0 bil/L Platelets &gt; 50 bil/L Bilirubin &lt; 4.0 time upper range normal INR &lt; 1.5 correctable vitamin K ( unless patient coumadin case high level acceptable ) AST ALT &lt; 6.0 time upper range normal Child 's A 56 liver score Child B 78 liver score , permit maximal tumor size 10 cm Previous liver resection ablative therapy permit . Life expectancy &gt; 3 month The volume uninvolved must least 700 cc Up five discrete liver tumor Patients must sign studyspecific inform consent form . If patient 's mental status precludes , write informed consent may give patient 's legal representative . Patients active hepatitis encephalopathy relate liver failure Prior radiation therapy right upper abdomen , preclude reirradiation liver . That , previous radiation therapy mean dose liver 15 Gy conventional fractionation deliver , previous dos critical normal structure would make reirradiation unsafe . The PI call question safety reirradiation . Eligible RFA alcohol ablation Eligible TACE Prior uncontrolled , life threaten malignancy within six month . Pregnancy permit , woman child bear age , pregnancy test acceptable method contraception warrant . Previous gastric , duodenal variceal bleed within past 2 month . Commencement coumadin use within past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Stereotactic Body Radiation</keyword>
	<keyword>Unresectable liver cancer</keyword>
	<keyword>Patients Hepatocellular Carcinoma</keyword>
</DOC>